Endocrine Abstracts

Authors agree that although mortality for COVID 19 is low, comorbidities may contribute to severe disease and mortality. Chinese center for disease control and prevention reported three times higher mortality in patients with diabetes. However, most studies do not take into account age of patients. Our study aimed to evaluate association of COVID in patients lesser than 65 years of age in two countries, India and United Kingdom with diabetes. We excluded patients with co-morbi...

Introduction: Glucocorticoid replacement in adrenal insufficiency may be achieved by administering thrice- daily hydrocortisone or once-daily very low dose (2-4 mg) prednisolone. Prednisolone’s longer half-life enables once-daily dosing, improving patient satisfaction and compliance. At very low doses, it has shown no difference in most markers of metabolic risk when compared with hydrocortisone. At Imperial College Healthcare NHS Trust (ICHNT), use of an eight-hour troug...

Introduction: Liberal glucocorticoid replacement therapy prevents Addisonian crises in individuals with adrenal insufficiency (AI). Prednisolone is six to eight times more potent than hydrocortisone. There is inter-individual variation in glucocorticoid metabolism wherein 5 mg prednisolone once-daily may result in over-replacement in most individuals, with subsequent long-term morbidity and mortality.Methods: Data from individuals on established predniso...

Introduction: Sodium Glucose Co-transporter 2 inhibitors (SGLT2i) are a novel class of glucose-lowering therapies that have demonstrated prognostic benefit in the management diabetes, heart failure and renal impairment. National Institute for Health and Clinical Excellence (NICE) guidance recommends offering SGLT2i, in addition to metformin, first-line in individuals with type 2 diabetes (T2D) and chronic heart failure/ established atherosclerotic cardiovascular disease. Howev...